

## Special Issue

# Transcription Factors: Role in Degenerative Diseases

### Message from the Guest Editor

Degenerative diseases are serious pathological conditions with critical social outcomes. In fact, neurodegenerative diseases as well as bone and musculoskeletal disorders, cardiovascular diseases, diabetes, and cancer affect a large part of the population. Unfortunately, therapeutic approaches are not able to counteract these degenerative diseases. Among the molecules involved in degenerative diseases, transcription factors play an important role in this context. Transcription factors, by acting on gene expression, can affect cellular processes and, thereby, can induce cellular injury, leading to degenerative diseases. However, transcription factors have been ignored by the pharmaceutical industry as drug design against them has proven difficult. The possibility to identify targeted drugs with higher affinity and specificity is an important goal to prevent degenerative diseases. In this Special Issue of *Molecules*, we will address the role of transcription factors in inducing cellular alterations in different degenerative diseases. Papers describing pharmaceutical approaches in this context are welcome too.

### Guest Editor

Dr. Maria Teresa Valenti

Department of Neurosciences, Biomedicine and Movement Sciences,  
University of Verona, 37128 Verona, Italy

### Deadline for manuscript submissions

closed (30 December 2019)



## Molecules

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/27394](https://mdpi.com/si/27394)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).